chemotherapy + PD-1 inhibitors

Chemotherapy + PD-1 inhibitors is a combination therapy approach that pairs traditional cytotoxic chemotherapy with immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) pathway. This combination strategy leverages potential synergistic effects between these treatment modalities. Chemotherapy can induce immunogenic cell death, increasing the availability of tumor antigens and potentially reducing immunosuppressive cells in the tumor microenvironment, while PD-1 inhibitors enhance T-cell function by blocking the inhibitory PD-1/PD-L1 interaction. This combination has shown significant improvements in clinical outcomes compared to chemotherapy alone, including longer progression-free survival (PFS) and overall survival (OS) in various cancer types, particularly non-small cell lung cancer (NSCLC).

Other names

PD-1 inhibitor plus chemotherapyPD1 inhibitor plus chemotherapyPD 1 inhibitor plus chemotherapyPD-(L)1 inhibitor plus chemotherapychemo-anti-PD-1 combinationchemo-anti-PD1 combinationchemo-anti-PD 1 combination